Traders should monitor upcoming clinical data in H1 2026 for AlloNK in refractory RA, which could serve as a key catalyst. Despite growing losses and zero revenue, the cash runway provides near-term stability, reducing immediate dilution risk.
Price Chart
Executive Summary
Artiva Biotherapeutics reported its full-year 2025 financial results, highlighting a net loss of $83.9 million, increased R&D spending, and a strong cash position of $108.0 million that funds operations into Q2 2027. The company emphasized clinical progress with AlloNK in refractory rheumatoid arthritis, including FDA Fast Track designation and upcoming data readouts in H1 2026, but reported zero revenue for the year.
Key Financial Metrics
Key Facts
- Net loss was $83.9 million in 2025 vs. $65.4 million in 2024
- Cash, cash equivalents, and investments totaled $108.0 million as of December 31, 2025, down from $185.4 million in 2024
- Cash runway extends into Q2 2027
- License and development support revenue was $0 in 2025 vs. $0.3 million in 2024
- R&D expenses increased to $69.5 million from $50.3 million in 2024
- Initial clinical response data in refractory RA expected in first half of 2026
- FDA interaction planned in first half of 2026 to discuss pivotal trial design
Financial Impact
Increased R&D spend by $19.2 million YoY; cash burn of ~$77.4 million (net loss plus non-cash items); revenue declined to zero
Risk Factors
- High cash burn with no current revenue stream
- Clinical data in H1 2026 may not meet expectations, risking valuation decline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253311 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access